• Clinical Technology
  • Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Nephrology
  • Neurology
  • Pulmonology

Transforming “what if” to “what is” with the Veradigm Network

News
Video

Our network connects providers, health plans, and life science companies to deliver seamless care that benefits everyone

Related Videos
"Vaccination is More of a Marathon than a Sprint"
Vaccines are for Kids, Booster Fatigue, and Other Obstacles to Adult Immunization
Related Content
Investigational Psychedelic RE104 for Postpartum Depression Delivers Positive Phase 2 Results: Reunion Neuroscience Update / image credit UVA Health Anita Clayton, MD

Investigational Psychedelic RE104 for Postpartum Depression Delivers Positive Phase 2 Results: Reunion Neuroscience Update

Grace Halsey
August 18th 2025
Article

In the RE104 group receiving the 30-mg dose, clinically meaningful reductions in the primary endpoint were seen on day 1 posttreatment and sustained through day 28 follow-up.

The Weekly Dose: New Endocrine Guidelines, Digital Asthma Gains, AI Trust Gap, GLP-1 & Dementia Risk, First CHE Treatment

The Weekly Dose: New Endocrine Guidelines, Digital Asthma Gains, AI Trust Gap, GLP-1 & Dementia Risk, First CHE Treatment

Sydney Jennings
August 15th 2025
Podcast

Explore the latest insights on diabetes in pregnancy, asthma management disparities, AI in health care, dementia risk reduction, and new eczema treatments.

Pharmacy-Based FIT Distribution Could Broaden CRC Screening, But Results Must be Delivered with Care, New Survey Reveals

Pharmacy-Based FIT Distribution Could Broaden CRC Screening, But Results Must be Delivered with Care, New Survey Reveals

Grace Halsey
August 18th 2025
Article

If FIT results indicated colonoscopy, respondents preferred personal follow-up vs digital; significant barriers to undergoing fear of the test and positive cancer finding were the most significant barriers to follow-up.

The Weekly Dose: Pediatric Vaccine Safety, Atopic Dermatitis, Dementia Risk, and Maternal Depression

The Weekly Dose: Pediatric Vaccine Safety, Atopic Dermatitis, Dementia Risk, and Maternal Depression

Sydney Jennings
August 7th 2025
Podcast

Insights on atopic dermatitis treatment preferences, the safety of childhood vaccines, maternal depression’s effect on parenting, and more.

Site Logo

Beyond Billing: Rethinking Revenue Cycle Strategies for Lasting Growth

August 18th 2025
Article
FDA Approves Semaglutide 2.4 mg for Treatment of MASH Without Cirrhosis

FDA Approves Semaglutide 2.4 mg for Treatment of MASH Without Cirrhosis

Patient Care Editorial Staff
August 16th 2025
Article

The accelerated approval for semaglutide 2.4 mg for the treatment of noncirrhotic MASH was based on part 1 of the phase 3 ESSENCE trial, which met its primary endpoints.

© 2025 MJH Life Sciences

All rights reserved.